The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2016-0903
Date:	31 May 2016
Product Name:	Infliximab
Therapeutic Area:	Immunology
Product Class:	Tumor necrosis factor (TNF) blocker
Condition(s) Studied:	Crohn's Disease
Protocol Number(s) and Title(s):	**NCT00094458**- Multicenter, Randomized, Double-Blind, Active Controlled Trial Comparing REMICADE® (Infliximab) and REMICADE plus Azathioprine to Azathioprine in the Treatment of Patients with Crohn's Disease Naive to both Immunomodulators and Biologic **NCT00207662**-A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNFa Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long-term Treatment of Patients With Moderately to Severely Active Crohn's Disease **NCT00207766**- A Randomized, Double-blind, Placebo-controlled Trial of Anti-TNF Chimeric Monoclonal Antibody (Infliximab, Remicade) in the Long Term Treatment of Patients With Fistulizing CROHN'S Disease **NCT00004941**- A Placebo-controlled, Repeated-dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients with Enterocutaneous Fistulae as a Complication of Crohn's Disease

Part 2: Data Availability	
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments:	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments:	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments:	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments:	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments:	

Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data are available for a data sharing request.	Yes

The YODA Project
Research Proposal Due Diligence Assessment

Part 4: Proposal Review	
Question:	**Response:**
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	